Obesity Treatment Market Size, Share and Growth Outlook 2026: By Treatment Type, By Drug Class, By Surgical Procedure, By Medical Device Type, By End User, Companies to 2034
The global Obesity Treatment Market size is forecast to increase from $20.85 Billion in 2026 to $98.89 Billion in 2034 at a CAGR of 21.48% between 2026 and 2034.
The Obesity Treatment market report provides detailed analysis and outlook of Obesity Treatment segments including By Treatment Type (Pharmacotherapy, Bariatric Surgery, Lifestyle Intervention Programs, Dietary Supplements, Medical Devices), By Drug Class (GLP-1 Receptor Agonists, Dual/Triple Agonists, Lipase Inhibitors, Phentermine-topiramate, Bupropion-naltrexone, MC4R Agonists), By Surgical Procedure (Sleeve Gastrectomy, Biliopancreatic Diversion with Duodenal Switch, Gastric Banding, Other Bariatric Surgeries), By Medical Device Type (Intragastric Balloons, Electrical Stimulation Systems), By End User (Hospitals and Clinics, Homecare Settings) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Obesity Treatment Industry Overview
Oral GLP-1 Therapies, Manufacturing Scalability, and Next-Generation Incretins Are Reshaping Obesity Management
The obesity treatment industry is experiencing one of the most significant transformations in pharmaceutical history as advances in incretin biology, oral drug delivery technologies, and metabolic therapeutics redefine the treatment landscape. The growing prevalence of obesity and associated metabolic disorders has accelerated investment in glucagon-like peptide-1 (GLP-1) receptor agonists, dual incretin therapies, and next-generation oral obesity medications. Pharmaceutical companies are increasingly prioritizing therapies that combine robust efficacy, patient convenience, manufacturing scalability, and broad accessibility. The emergence of oral incretin therapies represents a major shift away from exclusive reliance on injectable products, opening new opportunities for patient adoption and global treatment expansion.
Oral GLP-1 Therapies Are Expanding Patient Access to Weight Management
The development of oral obesity medications has become a critical strategic priority as pharmaceutical companies seek to overcome barriers associated with injectable therapies and broaden patient access. Oral formulations offer greater convenience while potentially expanding adoption among patients reluctant to use injectable treatments. This trend is demonstrated by the regulatory approval of the oral formulation of Wegovy developed by Novo Nordisk in the United Kingdom. As the first oral GLP-1 receptor agonist approved specifically for chronic weight management in the market, the product introduces a needle-free therapeutic alternative for obesity treatment. The approval highlights the growing commercial and clinical importance of oral incretin therapies within global obesity management strategies.
Small-Molecule Incretin Therapies Are Addressing Manufacturing Constraints
The rapid growth of obesity therapeutics has created unprecedented demand for manufacturing capacity, prompting pharmaceutical companies to develop scalable alternatives to biologically manufactured injectable products. Small-molecule incretin therapies offer significant advantages in production efficiency and supply chain scalability. This trend is exemplified by the clinical progress of orforglipron developed by Eli Lilly and Company. As the first non-peptide oral GLP-1 receptor agonist to demonstrate significant weight reduction in late-stage clinical trials, the therapy combines convenient administration with manufacturing processes based on traditional chemical synthesis. The ability to avoid the production constraints associated with biologic injectables positions oral small-molecule therapies as a potentially transformative advancement within obesity treatment.
Dual Incretin Therapies Are Expanding the Future Treatment Landscape
The development of therapies targeting multiple metabolic pathways simultaneously is emerging as a major area of innovation within obesity management. Dual agonist approaches seek to enhance therapeutic efficacy while expanding treatment options across diverse patient populations. This trend is illustrated by the advancement of VK2735 by Viking Therapeutics following regulatory alignment discussions with the U.S. Food and Drug Administration. The company's dual GIP/GLP-1 receptor agonist demonstrated substantial weight reduction during clinical evaluation and is progressing through development in both injectable and oral formulations. The simultaneous advancement of multiple delivery modalities highlights the industry's broader strategy of developing highly effective, flexible, and patient-centric obesity therapies.
Obesity Treatment Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Obesity Treatment market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim International GmbH, AstraZeneca PLC, Rhythm Pharmaceuticals, Inc., Currax Pharmaceuticals LLC, VIVUS LLC, Gelesis, Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd.. The Obesity Treatment market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Obesity Treatment industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Obesity Treatment industry include- Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim International GmbH, AstraZeneca PLC, Rhythm Pharmaceuticals, Inc., Currax Pharmaceuticals LLC, VIVUS LLC, Gelesis, Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd.. The Obesity Treatment market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Obesity Treatment Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Obesity Treatment market remains one of the strongest-performing segments in the country.
The US Obesity Treatment Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Obesity Treatment market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Obesity Treatment industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Obesity Treatment markets
Canada's strong Obesity Treatment sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Obesity Treatment market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Obesity Treatment Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Obesity Treatment market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Obesity Treatment population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Obesity Treatment industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Obesity Treatment market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Obesity Treatment sales through 2034
France Obesity Treatment companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Obesity Treatment Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Obesity Treatment distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Obesity Treatment Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Obesity Treatment market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Obesity Treatment industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Obesity Treatment industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Obesity Treatment Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Obesity Treatment market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Obesity Treatment market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Obesity Treatment Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Obesity Treatment Market Segmentation
By Treatment Type
Pharmacotherapy
Bariatric Surgery
Lifestyle Intervention Programs
Dietary Supplements
Medical Devices
By Drug Class
GLP-1 Receptor Agonists
Dual/Triple Agonists
Lipase Inhibitors
Phentermine-topiramate
Bupropion-naltrexone
MC4R Agonists
By Surgical Procedure
Sleeve Gastrectomy
Biliopancreatic Diversion with Duodenal Switch
Gastric Banding
Other Bariatric Surgeries
By Medical Device Type
Intragastric Balloons
Electrical Stimulation Systems
By End User
Hospitals and Clinics
Homecare Settings
Leading Companies in Obesity Treatment Industry (2026)
Novo Nordisk A/S
Eli Lilly and Company
Boehringer Ingelheim International GmbH
AstraZeneca PLC
Rhythm Pharmaceuticals, Inc.
Currax Pharmaceuticals LLC
VIVUS LLC
Gelesis, Inc.
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
Countries Included
The Obesity Treatment market report provides detailed analysis and outlook of Obesity Treatment segments including By Treatment Type (Pharmacotherapy, Bariatric Surgery, Lifestyle Intervention Programs, Dietary Supplements, Medical Devices), By Drug Class (GLP-1 Receptor Agonists, Dual/Triple Agonists, Lipase Inhibitors, Phentermine-topiramate, Bupropion-naltrexone, MC4R Agonists), By Surgical Procedure (Sleeve Gastrectomy, Biliopancreatic Diversion with Duodenal Switch, Gastric Banding, Other Bariatric Surgeries), By Medical Device Type (Intragastric Balloons, Electrical Stimulation Systems), By End User (Hospitals and Clinics, Homecare Settings) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Obesity Treatment Industry Overview
Oral GLP-1 Therapies, Manufacturing Scalability, and Next-Generation Incretins Are Reshaping Obesity Management
The obesity treatment industry is experiencing one of the most significant transformations in pharmaceutical history as advances in incretin biology, oral drug delivery technologies, and metabolic therapeutics redefine the treatment landscape. The growing prevalence of obesity and associated metabolic disorders has accelerated investment in glucagon-like peptide-1 (GLP-1) receptor agonists, dual incretin therapies, and next-generation oral obesity medications. Pharmaceutical companies are increasingly prioritizing therapies that combine robust efficacy, patient convenience, manufacturing scalability, and broad accessibility. The emergence of oral incretin therapies represents a major shift away from exclusive reliance on injectable products, opening new opportunities for patient adoption and global treatment expansion.
Oral GLP-1 Therapies Are Expanding Patient Access to Weight Management
The development of oral obesity medications has become a critical strategic priority as pharmaceutical companies seek to overcome barriers associated with injectable therapies and broaden patient access. Oral formulations offer greater convenience while potentially expanding adoption among patients reluctant to use injectable treatments. This trend is demonstrated by the regulatory approval of the oral formulation of Wegovy developed by Novo Nordisk in the United Kingdom. As the first oral GLP-1 receptor agonist approved specifically for chronic weight management in the market, the product introduces a needle-free therapeutic alternative for obesity treatment. The approval highlights the growing commercial and clinical importance of oral incretin therapies within global obesity management strategies.
Small-Molecule Incretin Therapies Are Addressing Manufacturing Constraints
The rapid growth of obesity therapeutics has created unprecedented demand for manufacturing capacity, prompting pharmaceutical companies to develop scalable alternatives to biologically manufactured injectable products. Small-molecule incretin therapies offer significant advantages in production efficiency and supply chain scalability. This trend is exemplified by the clinical progress of orforglipron developed by Eli Lilly and Company. As the first non-peptide oral GLP-1 receptor agonist to demonstrate significant weight reduction in late-stage clinical trials, the therapy combines convenient administration with manufacturing processes based on traditional chemical synthesis. The ability to avoid the production constraints associated with biologic injectables positions oral small-molecule therapies as a potentially transformative advancement within obesity treatment.
Dual Incretin Therapies Are Expanding the Future Treatment Landscape
The development of therapies targeting multiple metabolic pathways simultaneously is emerging as a major area of innovation within obesity management. Dual agonist approaches seek to enhance therapeutic efficacy while expanding treatment options across diverse patient populations. This trend is illustrated by the advancement of VK2735 by Viking Therapeutics following regulatory alignment discussions with the U.S. Food and Drug Administration. The company's dual GIP/GLP-1 receptor agonist demonstrated substantial weight reduction during clinical evaluation and is progressing through development in both injectable and oral formulations. The simultaneous advancement of multiple delivery modalities highlights the industry's broader strategy of developing highly effective, flexible, and patient-centric obesity therapies.
Obesity Treatment Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Obesity Treatment market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim International GmbH, AstraZeneca PLC, Rhythm Pharmaceuticals, Inc., Currax Pharmaceuticals LLC, VIVUS LLC, Gelesis, Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd.. The Obesity Treatment market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Obesity Treatment industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Obesity Treatment Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Obesity Treatment companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Obesity Treatment markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Obesity Treatment industry include- Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim International GmbH, AstraZeneca PLC, Rhythm Pharmaceuticals, Inc., Currax Pharmaceuticals LLC, VIVUS LLC, Gelesis, Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd.. The Obesity Treatment market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Obesity Treatment Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Obesity Treatment market remains one of the strongest-performing segments in the country.
The US Obesity Treatment Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Obesity Treatment market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Obesity Treatment industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Obesity Treatment markets
Canada's strong Obesity Treatment sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Obesity Treatment market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Obesity Treatment Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Obesity Treatment market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Obesity Treatment population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Obesity Treatment industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Obesity Treatment market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Obesity Treatment sales through 2034
France Obesity Treatment companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Obesity Treatment Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Obesity Treatment distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Obesity Treatment Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Obesity Treatment market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Obesity Treatment industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Obesity Treatment industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Obesity Treatment Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Obesity Treatment market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Obesity Treatment market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Obesity Treatment Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Obesity Treatment Market Segmentation
By Treatment Type
Pharmacotherapy
Bariatric Surgery
Lifestyle Intervention Programs
Dietary Supplements
Medical Devices
By Drug Class
GLP-1 Receptor Agonists
Dual/Triple Agonists
Lipase Inhibitors
Phentermine-topiramate
Bupropion-naltrexone
MC4R Agonists
By Surgical Procedure
Sleeve Gastrectomy
Biliopancreatic Diversion with Duodenal Switch
Gastric Banding
Other Bariatric Surgeries
By Medical Device Type
Intragastric Balloons
Electrical Stimulation Systems
By End User
Hospitals and Clinics
Homecare Settings
Leading Companies in Obesity Treatment Industry (2026)
Novo Nordisk A/S
Eli Lilly and Company
Boehringer Ingelheim International GmbH
AstraZeneca PLC
Rhythm Pharmaceuticals, Inc.
Currax Pharmaceuticals LLC
VIVUS LLC
Gelesis, Inc.
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Obesity Treatment Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Obesity Treatment Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL OBESITY TREATMENT MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Obesity Treatment Markets in 2026
3.2. Global Historic and Forecast Obesity Treatment Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Obesity Treatment Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Obesity Treatment Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Obesity Treatment Value Chain
CHAPTER 4- OBESITY TREATMENT MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Obesity Treatment Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- OBESITY TREATMENT MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Treatment Type
Pharmacotherapy
Bariatric Surgery
Lifestyle Intervention Programs
Dietary Supplements
Medical Devices
By Drug Class
GLP-1 Receptor Agonists
Dual/Triple Agonists
Lipase Inhibitors
Phentermine-topiramate
Bupropion-naltrexone
MC4R Agonists
By Surgical Procedure
Sleeve Gastrectomy
Biliopancreatic Diversion with Duodenal Switch
Gastric Banding
Other Bariatric Surgeries
By Medical Device Type
Intragastric Balloons
Electrical Stimulation Systems
By End User
Hospitals and Clinics
Homecare Settings
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA OBESITY TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Obesity Treatment Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Obesity Treatment Market Trends and Growth Opportunities to 2034
7.5. North America Obesity Treatment Market Size Outlook by Type
7.6. North America Obesity Treatment Market Size Outlook by Application
7.7. North America Obesity Treatment Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Obesity Treatment Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Obesity Treatment Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Obesity Treatment Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Obesity Treatment Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Obesity Treatment Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Obesity Treatment Companies
CHAPTER 8- EUROPE OBESITY TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Obesity Treatment Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Obesity Treatment Market Trends and Growth Opportunities to 2034
8.5. Europe Obesity Treatment Market Size Outlook by Type
8.6. Europe Obesity Treatment Market Size Outlook by Application
8.7. Europe Obesity Treatment Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Obesity Treatment Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Obesity Treatment Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Obesity Treatment Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Obesity Treatment Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Obesity Treatment Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Obesity Treatment Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Obesity Treatment Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Obesity Treatment Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Obesity Treatment Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Obesity Treatment Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Obesity Treatment Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Obesity Treatment Companies
CHAPTER 9- ASIA PACIFIC OBESITY TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Obesity Treatment Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Obesity Treatment Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Obesity Treatment Market Size Outlook by Type
9.6. Asia Pacific Obesity Treatment Market Size Outlook by Application
9.7. Asia Pacific Obesity Treatment Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Obesity Treatment Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Obesity Treatment Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Obesity Treatment Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Obesity Treatment Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Obesity Treatment Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Obesity Treatment Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Obesity Treatment Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Obesity Treatment Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Obesity Treatment Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Obesity Treatment Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Obesity Treatment Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Obesity Treatment Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA OBESITY TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Obesity Treatment Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Obesity Treatment Market Trends and Growth Opportunities to 2034
10.5. South and Central America Obesity Treatment Market Size Outlook by Type
10.6. South and Central America Obesity Treatment Market Size Outlook by Application
10.7. South and Central America Obesity Treatment Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Obesity Treatment Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Obesity Treatment Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Obesity Treatment Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Obesity Treatment Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Obesity Treatment Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Obesity Treatment Companies
CHAPTER 11- MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Obesity Treatment Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Obesity Treatment Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Obesity Treatment Market Size Outlook by Type
11.6. Middle East and Africa Obesity Treatment Market Size Outlook by Application
11.7. Middle East and Africa Obesity Treatment Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Obesity Treatment Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Obesity Treatment Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Obesity Treatment Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Obesity Treatment Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Obesity Treatment Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Obesity Treatment Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Obesity Treatment Industry
Novo Nordisk A/S
Eli Lilly and Company
Boehringer Ingelheim International GmbH
AstraZeneca PLC
Rhythm Pharmaceuticals, Inc.
Currax Pharmaceuticals LLC
VIVUS LLC
Gelesis, Inc.
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Obesity Treatment Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Obesity Treatment Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL OBESITY TREATMENT MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Obesity Treatment Markets in 2026
3.2. Global Historic and Forecast Obesity Treatment Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Obesity Treatment Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Obesity Treatment Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Obesity Treatment Value Chain
CHAPTER 4- OBESITY TREATMENT MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Obesity Treatment Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- OBESITY TREATMENT MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Treatment Type
Pharmacotherapy
Bariatric Surgery
Lifestyle Intervention Programs
Dietary Supplements
Medical Devices
By Drug Class
GLP-1 Receptor Agonists
Dual/Triple Agonists
Lipase Inhibitors
Phentermine-topiramate
Bupropion-naltrexone
MC4R Agonists
By Surgical Procedure
Sleeve Gastrectomy
Biliopancreatic Diversion with Duodenal Switch
Gastric Banding
Other Bariatric Surgeries
By Medical Device Type
Intragastric Balloons
Electrical Stimulation Systems
By End User
Hospitals and Clinics
Homecare Settings
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA OBESITY TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Obesity Treatment Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Obesity Treatment Market Trends and Growth Opportunities to 2034
7.5. North America Obesity Treatment Market Size Outlook by Type
7.6. North America Obesity Treatment Market Size Outlook by Application
7.7. North America Obesity Treatment Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Obesity Treatment Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Obesity Treatment Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Obesity Treatment Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Obesity Treatment Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Obesity Treatment Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Obesity Treatment Companies
CHAPTER 8- EUROPE OBESITY TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Obesity Treatment Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Obesity Treatment Market Trends and Growth Opportunities to 2034
8.5. Europe Obesity Treatment Market Size Outlook by Type
8.6. Europe Obesity Treatment Market Size Outlook by Application
8.7. Europe Obesity Treatment Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Obesity Treatment Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Obesity Treatment Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Obesity Treatment Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Obesity Treatment Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Obesity Treatment Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Obesity Treatment Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Obesity Treatment Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Obesity Treatment Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Obesity Treatment Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Obesity Treatment Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Obesity Treatment Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Obesity Treatment Companies
CHAPTER 9- ASIA PACIFIC OBESITY TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Obesity Treatment Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Obesity Treatment Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Obesity Treatment Market Size Outlook by Type
9.6. Asia Pacific Obesity Treatment Market Size Outlook by Application
9.7. Asia Pacific Obesity Treatment Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Obesity Treatment Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Obesity Treatment Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Obesity Treatment Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Obesity Treatment Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Obesity Treatment Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Obesity Treatment Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Obesity Treatment Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Obesity Treatment Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Obesity Treatment Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Obesity Treatment Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Obesity Treatment Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Obesity Treatment Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA OBESITY TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Obesity Treatment Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Obesity Treatment Market Trends and Growth Opportunities to 2034
10.5. South and Central America Obesity Treatment Market Size Outlook by Type
10.6. South and Central America Obesity Treatment Market Size Outlook by Application
10.7. South and Central America Obesity Treatment Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Obesity Treatment Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Obesity Treatment Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Obesity Treatment Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Obesity Treatment Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Obesity Treatment Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Obesity Treatment Companies
CHAPTER 11- MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Obesity Treatment Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Obesity Treatment Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Obesity Treatment Market Size Outlook by Type
11.6. Middle East and Africa Obesity Treatment Market Size Outlook by Application
11.7. Middle East and Africa Obesity Treatment Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Obesity Treatment Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Obesity Treatment Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Obesity Treatment Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Obesity Treatment Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Obesity Treatment Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Obesity Treatment Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Obesity Treatment Industry
Novo Nordisk A/S
Eli Lilly and Company
Boehringer Ingelheim International GmbH
AstraZeneca PLC
Rhythm Pharmaceuticals, Inc.
Currax Pharmaceuticals LLC
VIVUS LLC
Gelesis, Inc.
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
